Table 3.
Phase II clinical trials of neoadjuvant immunotherapy.
| Trial | Stage | Size | Intervention Used | ORR | MPR | pCR | Survival |
|---|---|---|---|---|---|---|---|
| CheckMate-159 (NCT02259621) [8] | IB–IIIA | 22 | Nivolumab | 10% | 45% | 10% | RFS at 18 months: 73% |
| LCMC3 (NCT02927301) [33] |
IB–IIIB | 181 | Atezolizumab | 7% | 20.4% | 6.8% | OS at 12 mo: 92% (stage II) 95% (stage III) |
| NEOSTAR (NCT03158129) [34] |
I–IIIA | 37 | Nivolumab + Ipilimumab vs. Nivolumab |
NI: 19%, N: 19% |
NI: 50%, N: 24% |
NI: 38%, N: 10% | NR |
| ChiCTR-OIC-17013726 [35] | IA–IIIB | 40 | Sintilimab | NR | 40.5% | 16.2% | NR |
ORR, objective response rate; MPR, major pathological response; pCR, pathological complete response; OS, overall survival.